Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Nuformix (NFX) Share Price

Price 0.325p on 20-11-2025 at 19:40:07
Change 0.00p 0%
Buy 0.34p
Sell 0.31p
Last Trade: Sell 44,000.00 at 0.322p
Day's Volume: 12,158,500
Last Close: 0.325p
Open: 0.325p
ISIN: GB00BYW79Y38
Day's Range 0.325p - 0.33p
52wk Range: 0.04p - 0.53p
Market Capitalisation: £6.86m
VWAP: 0.332245p
Shares in Issue: 2.11b

Nuformix (NFX) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 44,000 0.322p Ordinary
16:27:39 - 20-Nov-25
Sell* 379,130 0.324p Ordinary
15:57:49 - 20-Nov-25
Buy* 26,074 0.336p Ordinary
14:42:32 - 20-Nov-25
Sell* 2,186 0.324p Ordinary
12:33:18 - 20-Nov-25
Sell* 10,491 0.324p Ordinary
12:32:59 - 20-Nov-25
Sell* 1,000 0.324p Ordinary
12:32:12 - 20-Nov-25
Sell* 1,312,909 0.3244p Ordinary
12:14:03 - 20-Nov-25
Sell* 320,743 0.3244p Ordinary
11:47:09 - 20-Nov-25
Sell* 312,500 0.324p Ordinary
10:54:26 - 20-Nov-25
Sell* 220,000 0.324p Ordinary
10:44:57 - 20-Nov-25
See more Nuformix trades

Nuformix (NFX) Share Price History

Time period:
to
Date Open High Low Close Volume
20th Nov 2025 (Thu) 0.325 0.33 0.325 0.325 12,158,500
19th Nov 2025 (Wed) 0.35 0.36 0.325 0.325 87,419,147
18th Nov 2025 (Tue) 0.27 0.252 0.252 0.252 84,709,709
17th Nov 2025 (Mon) 0.29 0.29 0.27 0.275 22,654,870
14th Nov 2025 (Fri) 0.29 0.29 0.265 0.29 27,456,970
13th Nov 2025 (Thu) 0.295 0.29 0.28 0.29 24,931,535
12th Nov 2025 (Wed) 0.235 0.28 0.28 0.28 126,937,627
11th Nov 2025 (Tue) 0.355 0.355 0.3175 0.33 35,975,206
10th Nov 2025 (Mon) 0.365 0.37 0.355 0.355 26,513,552
7th Nov 2025 (Fri) 0.37 0.37 0.365 0.365 12,975,559
6th Nov 2025 (Thu) 0.39 0.39 0.345 0.37 69,316,096
5th Nov 2025 (Wed) 0.42 0.415 0.395 0.395 60,638,596
4th Nov 2025 (Tue) 0.485 0.53 0.42 0.425 136,435,708
3rd Nov 2025 (Mon) 0.40 0.505 0.48 0.485 128,493,038
31st Oct 2025 (Fri) 0.40 0.38 0.35 0.38 51,401,927
30th Oct 2025 (Thu) 0.33 0.38 0.38 0.38 43,572,294
29th Oct 2025 (Wed) 0.29 0.365 0.29 0.33 44,425,250
28th Oct 2025 (Tue) 0.275 0.295 0.27 0.29 61,005,059
27th Oct 2025 (Mon) 0.315 0.32 0.30 0.30 27,574,635
24th Oct 2025 (Fri) 0.315 0.315 0.31 0.31 23,261,271
23rd Oct 2025 (Thu) 0.305 0.335 0.305 0.315 46,364,432
22nd Oct 2025 (Wed) 0.265 0.32 0.265 0.305 55,731,677
21st Oct 2025 (Tue) 0.29 0.29 0.255 0.265 38,548,741
20th Oct 2025 (Mon) 0.285 0.29 0.265 0.265 25,251,853
See more Nuformix price history

Nuformix (NFX) Regulatory News

Date Source Headline
12th Nov 2025 7:01 am RNS Update re. US FDA ODD Application
12th Nov 2025 7:00 am RNS Results of Underwritten Open Offer
28th Oct 2025 7:00 am RNS Underwritten Open Offer
10th Oct 2025 7:00 am RNS Change of Auditor
25th Sep 2025 7:00 am RNS-R European Respiratory Society Congress Attendance
11th Aug 2025 7:00 am RNS US FDA ODD Application Submitted for NXP002
30th May 2025 2:24 pm RNS Total Voting Rights
29th May 2025 7:00 am RNS Confirmation of European ODD for NXP002
23rd May 2025 1:08 pm RNS Publication of a Prospectus
22nd May 2025 7:00 am RNS £210,000 Placing
See more Nuformix regulatory news

Nuformix (NFX) Share News

IN BRIEF: Nuformix raises GBP228,000 in open offer

12th Nov 2025 16:59

Nuformix PLC - London-based developer of treatments for fibrosis and oncology - Raises approximately GBP228,081 through an underwritten open offer at an issue price of 0.2 pence per share. Valid acceptances were received from qualifying shareholders for 465.8 million shares, representing more than four times the 114.0 million shares available. The full amount of 114.0 million shares will be issued in connection with the open offer. Company says applications for open offer shares under the excess application facility will be scaled back on a pro-rata basis. Expects dealings in the new shares to commence in London on Thursday. Read More

TRADING UPDATES: Celsius raises funds; Built Cybernetics acquisition

12th Nov 2025 15:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

IN BRIEF: Nuformix submits FDA drug designation application for NXP002

11th Aug 2025 12:11

Nuformix PLC - London-based developer of treatments for fibrosis and oncology - Submits US Food & Drug Administration orphan drug designation application for the NXP002 programme in idiopathic pulmonary fibrosis. If the orphan drug designation is granted, Nuformix may be eligible for some benefits, like tax credits for clinical trials or qualified clinical testing costs. Read More

Nuformix shares fall despite EU orphan drug status for lead treatment

29th May 2025 18:21

(Alliance News) - Nuformix PLC on Thursday said its lead programme, NXP002, has been granted orphan drug designation by the European Medicines Agency for the treatment of idiopathic pulmonary fibrosis. Read More

Nuformix interim loss widens as focused on advancing assets

2nd May 2025 12:19

(Alliance News) - Nuformix PLC on Friday said it has continued to "advance and exploit" assets in its portfolio, two days after noting a positive opinion from an EU committee for NXP002. Read More

See more Nuformix news
FTSE 100 Latest
Value9,527.65
Change20.24

Login to your account

Forgot Password?

Not Registered